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Allelic variants implicated in drug absorption, distribution,
metabolism, and excretion (ADME) affect drug pharmacoki-
netic variability and have been increasingly recognized as
important factors in medical therapy. Our recently published
study found an association of thrombotic microangiopathy
(TMA) with high sirolimus serum levels in a cohort of 177
patients who received sirolimus and tacrolimus as GVHD
prophylaxis following allogeneic transplantation. By multi-
variable analysis, increased risk of TMA was associated with
day 14 serum sirolimus levels, prior aGVHD, and myeloa-
blative conditioning. In the current study we explore the
possible inﬂuence of ADME variants on sirolimus levels and
development of TMA in the same patient cohort.
We obtained archived DNA samples from the patients on our
TMA study and analyzed them using the iPLEX ADME PGx
panel and the MassARRAY Compact Analyzer. This panel is
based on the PharmADME Working Group list and covers
>99% of the Pharma ADME Core list; it interrogates 188
mutations and 12 copy number variation assays (in 36
pharmacogenetically relevant genes). Sirolimus levels were
measured at least weekly until day 100 with dose adjust-
ments made for target levels and/or clinical toxicity. Possible
associations between early sirolimus serum levels (day +14)
and assays were evaluated by the Kruskal-Wallis (non-
parametric) test and the false discovery rate was used to
control for multiple comparisons.
Using this Panel, 179 samples were genotyped, of which 173
showed high quality data. The average call rate for these
samples was 98.85% over 200 assays, with a median call rate
of 100%. Of these assays, 66 variants were identiﬁed that may
be of relevance to sirolimus metabolism; other assays were
excluded due to homzygosity or >10 % missing data. Using
this panel, we found 3 assays showing an association with
sirolimus drug level, rs1057910 (CYP2C9*3) at P¼ .04,
rs1799931 (NAT2*7) at P¼ .03, and rs2032582 (ABCB1
2677G>A/T) at P¼ .007. In addition, the 0-copy haplotype of
UGT2B17 also showed higher levels of sirolimus (P¼ .02).
These assays were also tested for an association with TMA,
showing a trend for increased TMA in the rs1799931
(NAT2*7) (P ¼ .08). However, after adjustment for multiple
testing, only rs2032582 maintained statistical signiﬁcance
due to the small sample size.
In conclusion, this pilot study of the iPLEX ADME PGx panel
showed feasiblity and provided high quality data. Despite the
limitation of small sample size, several genetic variants were
implicated in sirolimus levels and may warrant further
investigation. Future analysis should focus on speciﬁc gene
clusters or pathways and will require a large cohort to power
validation and training sets.443
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Introduction: Acute graft versus host disease (aGVHD) is
mediatedbyallogeneicTcell responses.Wehypothesized that
peripheral blood expansion of activated effector memory T
cell populations (TEM) following allogeneic hematopoietic
cell transplantation (HCT)would serve as a useful predictor of
aGVHD.
Methods: T cells were characterized in peripheral blood
samples from 16 consecutive pediatric allogeneic hemato-
poietic cell transplant (HCT) recipients. Samples were
collected prior to transplant and weekly following HCT until
day +42. Samples were incubated with ﬂuorochrome-
conjugated monoclonal antibodies directed against CD3,
CD8, CD38, CD45RA and CCR7, followed by red cell lysis and
ﬁxation. Samples were analyzed by ﬂow cytometry on
a FACSCanto ll ﬂow cytometer (BD Biosciences). Data was
analyzed using FCS Express (De Novo Software). TEM were
deﬁned as CD3+ lymphocytes which lacked expression of
CD45RA and CCR7. CD38 was used as a marker of activation.
Results: Patients had less than 65% of CD8+ CD38 bright
TEMs prior to transplant except for 1 patient with HLH who
had 99.8%, and was excluded from analysis. Patients who
developed aGVHD (n¼5), engraftment syndrome (n¼2), or
neither (n¼8) were observed to develop median maximum
expansions of CD8+ CD38bright TEM prior to or on the day of
diagnosis of aGVHD, or before day +42, of 49 cells/mcl (range
21-87), 5 cells/mcL (range 0.3-34) and 98cells/mcL (range
0.04-197), respectively (P ¼ .02, GVHD versus neither GVHD
nor engraftment syndrome). We observed that an absolute
number of CD8+ CD38 bright TEM greater than 20cells/mcL
was predictive of aGVHD with sensitivity of 100%, speciﬁcity
of 80%, and a negative predictive value of 100%. The cumu-
lative incidence of aGVHD in patients with greater than 20
CD8+ CD38 bright TEMs/mcL was 71%, and in patients with
less than 20cells/mcL, 0% (P < .01).
Conclusion: Quantiﬁcation of peripheral blood CD8+ CD38
bright TEM is a novel predictor of aGVHD.444
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